Form 144/A PALVELLA THERAPEUTICS, Filed by: Goin Kathleen
Tweet
Share
E-mailATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Palvella files first NDA module for rare lymphatic malformation drug
- AvePoint Research Reveals AI Visibility Gaps Have Nearly Tripled as AI Agents Scale and Almost Half of Enterprise Employees Now Rely on Agents Daily or Weekly
- FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
